Can the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockers

Pharmacotherapy

Volumn 25, Issue 4, 2005, Pages 531-539

  Epstein, Benjamin J ^a,b,c   Gums, John G ^a,b  

^a Department of Pharmacology and Toxicology   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Angiotensin II receptor blockers; ARBs; Blood pressure control; Renin angiotensin system; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CHLORTALIDONE; CLOPIDOGREL; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METOPROLOL; RAMIPRIL; TELMISARTAN; URAPIDIL; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DISABILITY; DRUG COST; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; HUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; UNITED STATES;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 16444377632     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.4.531.61022     Document Type: Review

References (44)

1. American Heart Association. Heart disease and stroke statistics-2005 update. Available from http://www.americanheart.org. Accessed January 31, 2005.
2. Hurst W. The heart, arteries and veins, 10th ed. New York: McGraw-Hill, 2002.
3. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-44.
4. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000;342:145-53.
5. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet 2001;358:1033-41.
6. Chobanian AV, Bakris GI, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52.
7. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy [online exclusive article]. Hypertension 2001;38:e28-32. Available from http://hyper.ahajournals.org/cgi/reprint/38/6/e28.
8. Moutsatsos GD. More hype than HOPE [letter]. Hypertension 2003;41:4.
9. Staessen JA, Wang J. Blood-pressure lowering for the secondary prevention of stroke. Lancet 2001;358:1026-7.
10. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomised trial. Lancet 1999;353:611-16.
11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97.
12. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
13. Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
14. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
15. Hansson L, Lindholm LH, Ekboom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish trial in old patients with hypertension-2 study. Lancet 1999;354:1751-6.
16. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. New Engl J Med 2003;348:583-92.
17. Brown MJ, Brown J. Does angiotensin-II protect against strokes? Lancet 1986;2:427-9.
18. Messerli FH, Grossman E, Lever AF. Do thiazide diuretics confer specific protection against strokes? Arch Intern Med 2003;163:2557-60.
19. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004;43:1343-7.
20. The Medical Research Council Working Party. The MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97-104.
21. The Medical Research Council Working Party. The MRC trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.
22. Kostis JB, Berge KG, Davis BR, Hawkins CM, Probstfield J. Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). Am J Hypertens 1995;8:1147-53.
23. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-51.
24. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993;24:543-8.
25. Eriksson S, Olofsson BO, Wester PO, et al. Atenolol in secondary prevention after stroke. Cerebrovasc Dis 1995;5:21-5.
26. Unger T. Neurohormonal modulation in cardiovascular disease. Am Heart J 2000;139:S2-8.
27. 1RA) be more protective than angiotensin converting enzyme inhibitor (ACEI)? Nieren Hochblutdruck Krankheiten 2000;29:S545-54.
28. 2 receptor ligands: do they have potential as future treatments for neurological disease? CNS Drugs 2002;16:145-53.
29. Dai WJ, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999;30:2391-9.
30. 1 receptor blockade on neurological outcome after focal brain ischemia [abstr]. Hypertension 2000;36:256.
31. 2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol 1994;24:937-40.
32. Dalmay F, Mazouz H, Allard J, Pesteil F, Achard JM, Fournier A. Non AT(1)-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. J Renin Angiotensin Aldosterone Syst 2001;2:103-6.
33. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
34. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
35. Furberg CD. Late-breaking clinical trials II. Presented at the American College of Cardiology 53rd scientific session, 2004. New Orleans, LA, March 7-10, 2004.
36. LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
37. Dahlof B, Devereux RB, de Faire U, et al. The losartan intervention for endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. Am J Hypertens 1997;10:705-13.
38. Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
39. Schrader J, Luders S, Kulschewski A, et al. Acute candesartan cilexetil therapy in stroke survivors study group. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003;34:1699-703.
40. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965;14:61-5.
41. Mann J, Julius S. The valsartan antihypertensive long-term use evaluation (VALUE) trial of cardiovascular events in hypertension: rationale and design. Blood Press 1998;7:176-83.
42. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-51.
43. ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease. ONTARGET/TRANSCEND trials. Am Heart J 2004;148:52-61.
44. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke 2004;35:776-85.